J. Safra Sarasin Holding AG Has $782,000 Stock Holdings in Axsome Therapeutics, Inc. $AXSM

J. Safra Sarasin Holding AG decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 37.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 4,629 shares of the company’s stock after selling 2,754 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Axsome Therapeutics were worth $782,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Axsome Therapeutics by 45.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock worth $275,763,000 after buying an additional 472,422 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after acquiring an additional 609,516 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Axsome Therapeutics by 28.6% in the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after acquiring an additional 282,937 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Axsome Therapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock valued at $184,544,000 after acquiring an additional 12,549 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after acquiring an additional 52,483 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Activity

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 49,670 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $241.01, for a total value of $11,970,966.70. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at approximately $1,742,261.29. The trade was a 87.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ari Maizel sold 7,500 shares of the stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the sale, the insider directly owned 7,500 shares of the company’s stock, valued at approximately $1,368,150. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 163,352 shares of company stock worth $38,598,262. 20.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Robert W. Baird boosted their price objective on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $272.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Mizuho lifted their price target on Axsome Therapeutics from $228.00 to $310.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Guggenheim boosted their price target on Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Finally, UBS Group boosted their price target on Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.05.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $235.26 on Wednesday. The firm has a market cap of $12.11 billion, a PE ratio of -63.07 and a beta of 0.60. The firm’s fifty day moving average is $237.45 and its 200-day moving average is $196.83. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business’s revenue for the quarter was up 57.4% compared to the same quarter last year. Sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.43 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.